Electrochemotherapy in pancreatic adenocarcinoma treatment: pre-clinical and clinical studies

Sabrina Bimonte, Maddalena Leongito, Vincenza Granata, Antonio Barbieri, Vitale Del Vecchio, Michela Falco, Aurelio Nasto, Vittorio Albino, Mauro Piccirillo, Raffaele Palaia, Alfonso Amore, Raimondo di Giacomo, Secondo Lastoria, Sergio Venanzio Setola, Roberta Fusco, Antonella Petrillo, Francesco Izzo, Sabrina Bimonte, Maddalena Leongito, Vincenza Granata, Antonio Barbieri, Vitale Del Vecchio, Michela Falco, Aurelio Nasto, Vittorio Albino, Mauro Piccirillo, Raffaele Palaia, Alfonso Amore, Raimondo di Giacomo, Secondo Lastoria, Sergio Venanzio Setola, Roberta Fusco, Antonella Petrillo, Francesco Izzo

Abstract

Background: Pancreatic adenocarcinoma is currently one of the deadliest cancers with high mortality rate. This disease leads to an aggressive local invasion and early metastases, and is poorly responsive to treatment with chemotherapy or chemo-radiotherapy. Radical resection is still the only curative treatment for pancreatic cancer, but it is generally accepted that a multimodality strategy is necessary for its management. Therefore, new alternative therapies have been considered for local treatment.

Conclusions: Chemotherapeutic resistance in pancreatic cancer is associated to a low penetration of drugs into tumour cells due to the presence of fibrotic stroma surrounding cells. In order to increase the uptake of chemotherapeutic drugs into tumour cells, electrochemotherapy can be used for treatment of pancreatic adenocarcinoma leading to an increased tumour response rate. This review will summarize the published papers reported in literature on the efficacy and safety of electrochemotherapy in pre-clinical and clinical studies on pancreatic cancer.

Keywords: bleomycin; clinical study; efficacy; electrochemotherapy; pancreatic carcinoma; pre-clinical study; safety.

References

    1. 1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765–81.
    2. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46:765–81.
    1. 2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69–90.
    2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
    1. 3. Krejs GJ. Pancreatic cancer: epidemiology and risk factors. Dig Dis 2010; 28: 355–8.
    2. Krejs GJ. Pancreatic cancer: epidemiology and risk factors. Dig Dis. 2010;28:355–8.
    1. 4. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009; 27: 5513–8.
    2. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W. et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009;27:5513–8.
    1. 5. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403–13.
    2. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR. et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–13.
    1. 6. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817–25.
    2. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.
    1. 7. Neumann E, Kakorin S, Toensing K. Fundamentals of electroporative delivery of drugs and genes. Bioelectrochem Bioenerg 1999; 48: 3–16.
    2. Neumann E, Kakorin S, Toensing K. Fundamentals of electroporative delivery of drugs and genes. Bioelectrochem Bioenerg. 1999;48:3–16.
    1. 8. Orlowski S, Mir LM. Cell electropermeabilization: a new tool for biochemical and pharmacological studies. Biochim Biophys Acta 1993; 1154: 51–63.
    2. Orlowski S, Mir LM. Cell electropermeabilization: a new tool for biochemical and pharmacological studies. Biochim Biophys Acta. 1993;1154:51–63.
    1. 9. Gehl J. Electroporation: theory and methods, perspectives for drug delivery, gene therapy and research. Acta Physiol Scand 2003; 177: 437–47.
    2. Gehl J. Electroporation: theory and methods perspectives for drug delivery gene therapy and research. Acta Physiol Scand. 2003;177:437–47.
    1. 10. Mir LM, Orlowski S, Belehradek J Jr, Paoletti C. Electrochemotherapy potentiation of antitumour effect of bleomycin by local electric pulses. Eur J Cancer 1991; 27: 68–72.
    2. Mir LM, Orlowski S, Belehradek J Jr, Paoletti C. Electrochemotherapy potentiation of antitumour effect of bleomycin by local electric pulses. Eur J Cancer. 1991;27:68–72.
    1. 11. Sersa G, Novakovic S, Miklavcic D. Potentiation of bleomycin antitumor effectiveness by electrotherapy. Cancer Lett 1993; 69: 81–4.
    2. Sersa G, Novakovic S, Miklavcic D. Potentiation of bleomycin antitumor effectiveness by electrotherapy. Cancer Lett. 1993;69:81–4.
    1. 12. Nanda GS, Sun FX, Hofmann GA, Hoffman RM, Dev SB. Electroporation enhances therapeutic efficacy of anticancer drugs: treatment of human pancreatic tumor in animal model. Anticancer Res 1998; 18(3A): 1361–6.
    2. Nanda GS, Sun FX, Hofmann GA, Hoffman RM, Dev SB. Electroporation enhances therapeutic efficacy of anticancer drugs: treatment of human pancreatic tumor in animal model. Anticancer Res. 1998;18((3A)):1361–6.
    1. 13. Jaroszeski MJ, Illingworth P, Pottinger C, Hyacinthe M, Heller R. Electrically mediated drug delivery for treating subcutaneous and orthotopic pancreatic adenocarcinoma in a hamster model. Anticancer Res 1999; 19(2A): 989–94.
    2. Jaroszeski MJ, Illingworth P, Pottinger C, Hyacinthe M, Heller R. Electrically mediated drug delivery for treating subcutaneous and orthotopic pancreatic adenocarcinoma in a hamster model. Anticancer Res. 1999;19((2A)):989–94.
    1. 14. Liu X, Tian X, Wang F, Ma Y, Kornmann M, Yang Y. BRG1 promotes chemoresistance of pancreatic cancer cells through crosstalking with Akt signalling. Eur J Cancer 2014; 50: 2251–62.
    2. Liu X, Tian X, Wang F, Ma Y, Kornmann M, Yang Y. BRG1 promotes chemoresistance of pancreatic cancer cells through crosstalking with Akt signalling. Eur J Cancer. 2014;50:2251–62.
    1. 15. Granata V, Fusco R, Piccirillo M, Palaia R, Petrillo A, Lastoria S, et al. Electrochemotherapy in locally advanced pancreatic cancer: Preliminary results. Int J Surg 2015; 18: 230–6.
    2. Granata V, Fusco R, Piccirillo M, Palaia R, Petrillo A, Lastoria S. et al. Electrochemotherapy in locally advanced pancreatic cancer: Preliminary results. Int J Surg. 2015;18:230–6.
    1. 16. Miklavcic D, Sersa G, Brecelj E, Gehl J, Soden D, Bianchi G, et al. Electrochemotherapy: technological advancements for efficient electropo-ration-based treatment of internal tumors. Med Biol Eng Comput 2012; 50: 1213–25.
    2. Miklavcic D, Sersa G, Brecelj E, Gehl J, Soden D, Bianchi G. et al. Electrochemotherapy: technological advancements for efficient electropo-ration-based treatment of internal tumors. Med Biol Eng Comput. 2012;50:1213–25.
    1. 17. Girelli R, Prejano S, Cataldo I, Corbo V, Martini L, Scarpa A, et al. Feasibility and safety of electrochemotherapy (ECT) in the pancreas: a pre-clinical investigation. Radiol Oncol 2015; 49: 147–54.
    2. Girelli R, Prejano S, Cataldo I, Corbo V, Martini L, Scarpa A. et al. Feasibility and safety of electrochemotherapy (ECT) in the pancreas: a pre-clinical investigation. Radiol Oncol. 2015;49:147–54.
    1. 18. Jaroszeski MJ, Dang V, Pottinger C, Hickey J, Gilbert R, Heller R. Toxicity of anticancer agents mediated by electroporation in vitro. Anticancer Drugs 2000; 11: 201–8.
    2. Jaroszeski MJ, Dang V, Pottinger C, Hickey J, Gilbert R, Heller R. Toxicity of anticancer agents mediated by electroporation in vitro. Anticancer Drugs. 2000;11:201–8.
    1. 19. Cadossi R, Ronchetti M, Cadossi M. Locally enhanced chemotherapy by electroporation: clinical experiences and perspective of use of electrochemotherapy. Future Oncol 2014; 10: 877–90.
    2. Cadossi R, Ronchetti M, Cadossi M. Locally enhanced chemotherapy by electroporation: clinical experiences and perspective of use of electrochemotherapy. Future Oncol. 2014;10:877–90.
    1. 20. Miklavcic D, Mali B, Kos B, Heller R, Sersa G. Electrochemotherapy: from the drawing board into medical practice. Biomed Eng Online 2014; 13: 29.
    2. Miklavcic D, Mali B, Kos B, Heller R, Sersa G. Electrochemotherapy: from the drawing board into medical practice. Biomed Eng Online. 2014;13:29.
    1. 21. Gehl J, Skovsgaard T, Mir LM. Enhancement of cytotoxicity by electropermeabilization: an improved method for screening drugs. Anticancer Drugs 1998; 9: 319–25.
    2. Gehl J, Skovsgaard T, Mir LM. Enhancement of cytotoxicity by electropermeabilization: an improved method for screening drugs. Anticancer Drugs. 1998;9:319–25.
    1. 22. Poddevin B, Orlowski S, Belehradek J Jr, Mir LM. Very high cytotoxicity of bleomycin introduced into the cytosol of cells in culture. Biochem Pharmacol 1991; 42(Suppl): S67-75.
    2. Poddevin B, Orlowski S, Belehradek J Jr, Mir LM. Very high cytotoxicity of bleomycin introduced into the cytosol of cells in culture. Biochem Pharmacol. 1991;42(Suppl):S67–75.
    1. 23. Sersa G, Cemazar M, Miklavcic D. Antitumor effectiveness of electrochemo-therapy with cis-diamminedichloroplatinum(II) in mice. Cancer Res 1995; 55: 3450–5.
    2. Sersa G, Cemazar M, Miklavcic D. Antitumor effectiveness of electrochemo-therapy with cis-diamminedichloroplatinum(II) in mice. Cancer Res. 1995;55:3450–5.
    1. 24. Larkin JO, Collins CG, Aarons S, Tangney M, Whelan M, O’Reily S, et al. Electrochemotherapy: aspects of preclinical development and early clinical experience. Ann Surg 2007; 245: 469–79.
    2. Larkin JO, Collins CG, Aarons S, Tangney M, Whelan M, O’Reily S. et al. Electrochemotherapy: aspects of preclinical development and early clinical experience. Ann Surg. 2007;245:469–79.
    1. 25. Bisht S, Feldmann G, Soni S, Ravi R, Karikar C, Maitra A. Polymeric nanoparticle-encapsulated curcumin (“nanocurcumin”): a novel strategy for human cancer therapy. J Nanobiotechnology 2007; 5: 3.
    2. Bisht S, Feldmann G, Soni S, Ravi R, Karikar C, Maitra A. Polymeric nanoparticle-encapsulated curcumin (“nanocurcumin”): a novel strategy for human cancer therapy. J Nanobiotechnology. 2007;5:3.
    1. 26. Kishore B, Khare P, Gupta RJ, Bisht S, Majumdar K. Hemoglobin E disease in North Indian population: a report of 11 cases. Hematology 2007; 12: 343–7.
    2. Kishore B, Khare P, Gupta RJ, Bisht S, Majumdar K. Hemoglobin E disease in North Indian population: a report of 11 cases. Hematology. 2007;12:343–7.
    1. 27. Bimonte S, Leongito M, Barbieri A, Del Vecchio V, Barbieri M, Albino V, et al. Inhibitory effect of (-)-epigallocatechin-3-gallate and bleomycin on human pancreatic cancer MiaPaca-2 cell growth. Infect Agent Cancer 2015; 10: 22.
    2. Bimonte S, Leongito M, Barbieri A, Del Vecchio V, Barbieri M, Albino V. et al. Inhibitory effect of (-)-epigallocatechin-3-gallate and bleomycin on human pancreatic cancer MiaPaca-2 cell growth. Infect Agent Cancer. 2015;10:22.
    1. 28. Bower M, Sherwood L, Li Y, Martin R. Irreversible electroporation of the pancreas: definitive local therapy without systemic effects. J Surg Oncol 2011; 104: 22–8.
    2. Bower M, Sherwood L, Li Y, Martin R. Irreversible electroporation of the pancreas: definitive local therapy without systemic effects. J Surg Oncol. 2011;104:22–8.
    1. 29. Charpentier KP, Wolf F, Noble L, Winn B, Resnick M, Dupuy DE. Irreversible electroporation of the pancreas in swine: a pilot study. HPB (Oxford) 2010; 12: 348–51.
    2. Charpentier KP, Wolf F, Noble L, Winn B, Resnick M, Dupuy DE. Irreversible electroporation of the pancreas in swine: a pilot study. HPB (Oxford) 2010;12:348–51.
    1. 30. Martin RC. Use of irreversible electroporation in unresectable pancreatic cancer. Hepatobiliary Surg Nutr 2015; 4: 211–5.
    2. Martin RC. Use of irreversible electroporation in unresectable pancreatic cancer. Hepatobiliary Surg Nutr. 2015;4:211–5.
    1. 31. Charpentier KP, Wolf F, Noble L, Winn B, Resnick M, Dupuy DE. Irreversible electroporation of the liver and liver hilum in swine. HPB (Oxford) 2011; 13: 168–73.
    2. Charpentier KP, Wolf F, Noble L, Winn B, Resnick M, Dupuy DE. Irreversible electroporation of the liver and liver hilum in swine. HPB (Oxford) 2011;13:168–73.
    1. 32. Jose A, Sobrevals L, Ivorra A, Fillat C. Irreversible electroporation shows efficacy against pancreatic carcinoma without systemic toxicity in mouse models. Cancer Lett 2012; 317: 16–23.
    2. Jose A, Sobrevals L, Ivorra A, Fillat C. Irreversible electroporation shows efficacy against pancreatic carcinoma without systemic toxicity in mouse models. Cancer Lett. 2012;317:16–23.
    1. 33. Philips P, Li Y, Li S, St Hill CR, Martin RC. Efficacy of irreversible electroporation in human pancreatic adenocarcinoma: advanced murine model. Mol Ther Methods Clin Dev 2015; 2: 15001.
    2. Philips P, Li Y, Li S, Hill CR, Martin RC. Efficacy of irreversible electroporation in human pancreatic adenocarcinoma: advanced murine model. Mol Ther Methods Clin Dev. 2015;2:15001.
    1. 34. Philips P, Li Y, Martin RC 2nd. Low-energy DC current ablation in a mouse tumor model. Meth Mol Biol 2014; 1121: 257–65.
    2. Philips P, Li Y, Martin RC. Low-energy DC current ablation in a mouse tumor model. Meth Mol Biol. (2nd) 2014;1121:257–65.
    1. 35. Sersa G, Cemazar M, Snoj M. Electrochemotherapy of tumours. Curr Oncol 2009; 16: 34–5.
    2. Sersa G, Cemazar M, Snoj M. Electrochemotherapy of tumours. Curr Oncol. 2009;16:34–5.
    1. 36. Roux S, Bernat C, Al-Sakere B, Ghiringhelli F, Opolon P, Carpentier AF, et al. Tumor destruction using electrochemotherapy followed by CpG oligode-oxynucleotide injection induces distant tumor responses. Cancer Immunol Immunother 2008; 57: 1291–300.
    2. Roux S, Bernat C, Al-Sakere B, Ghiringhelli F, Opolon P, Carpentier AF. et al. Tumor destruction using electrochemotherapy followed by CpG oligode-oxynucleotide injection induces distant tumor responses. Cancer Immunol Immunother. 2008;57:1291–300.
    1. 37. Dev SB, Hofmann GA, Nanda GS. Treatment of human pancreatic tumors xenografted in nude mice by chemotherapy combined with pulsed electric fields. Methods Mol Med 2000; 37: 277–83.
    2. Dev SB, Hofmann GA, Nanda GS. Treatment of human pancreatic tumors xenografted in nude mice by chemotherapy combined with pulsed electric fields. Methods Mol Med. 2000;37:277–83.
    1. 38. Tafuto S, von Arx C, De Divitiis C, Tracey Maura C, Palaia R, Albino V, et al. Electrochemotherapy as a new approach on pancreatic cancer and on liver metastases. Int J Surg 2015; 21(Suppl 1): S78-82.
    2. Tafuto S, von Arx C, De Divitiis C, Tracey Maura C, Palaia R, Albino V. et al. Electrochemotherapy as a new approach on pancreatic cancer and on liver metastases. Int J Surg. 2015;21(Suppl 1):S78–82.
    1. 39. Edhemovic I, Gadzijev EM, Brecelj E, Miklavcic D, Kos B, Zupanic A, et al. Electrochemotherapy: a new technological approach in treatment of metastases in the liver. Technol Cancer Res Treat 2011; 10: 475–85.
    2. Edhemovic I, Gadzijev EM, Brecelj E, Miklavcic D, Kos B, Zupanic A. et al. Electrochemotherapy: a new technological approach in treatment of metastases in the liver. Technol Cancer Res Treat. 2011;10:475–85.
    1. 40. Girelli R, Frigerio I, Salvia R, Barbi E, Tinazzi Martini P, Bassi C. Feasibility and safety of radiofrequency ablation for locally advanced pancreatic cancer. Br J Surg. 2010; 97: 220–5.
    2. Girelli R, Frigerio I, Salvia R, Barbi E, Tinazzi Martini P, Bassi C. Feasibility and safety of radiofrequency ablation for locally advanced pancreatic cancer. Br J Surg. 2010;97:220–5.
    1. 41. Girelli R, Frigerio I, Giardino A, Regi P, Gobbo S, Malleo G, et al. Results of 100 pancreatic radiofrequency ablations in the context of a multimodal strategy for stage III ductal adenocarcinoma. Langenbecks Arch Surg 2013; 398: 63–9.
    2. Girelli R, Frigerio I, Giardino A, Regi P, Gobbo S, Malleo G. et al. Results of 100 pancreatic radiofrequency ablations in the context of a multimodal strategy for stage III ductal adenocarcinoma. Langenbecks Arch Surg. 2013;398:63–9.
    1. 42. Giardino A, Girelli R, Frigerio I, Regi P, Cantore M, Alessandra A, et al. Triple approach strategy for patients with locally advanced pancreatic carcinoma. HPB (Oxford) 2013; 15: 623–7.
    2. Giardino A, Girelli R, Frigerio I, Regi P, Cantore M, Alessandra A. et al. Triple approach strategy for patients with locally advanced pancreatic carcinoma. HPB (Oxford) 2013;15:623–7.
    1. 43. Cantore M, Girelli R, Mambrini A, Frigerio I, Boz G, Salvia R, et al. Combined modality treatment for patients with locally advanced pancreatic adenocarcinoma. Br J Surg 2012; 99: 1083–8.
    2. Cantore M, Girelli R, Mambrini A, Frigerio I, Boz G, Salvia R. et al. Combined modality treatment for patients with locally advanced pancreatic adenocarcinoma. Br J Surg. 2012;99:1083–8.
    1. 44. Matsui Y, Nakagawa A, Kamiyama Y, Yamamoto K, Kubo N, Nakase Y. Selective thermocoagulation of unresectable pancreatic cancers by using radiofrequency capacitive heating. Pancreas 2000; 20: 14–20.
    2. Matsui Y, Nakagawa A, Kamiyama Y, Yamamoto K, Kubo N, Nakase Y. Selective thermocoagulation of unresectable pancreatic cancers by using radiofrequency capacitive heating. Pancreas. 2000;20:14–20.
    1. 45. Young SJ. Irreversible electroporation and the pancreas: What we know and where we are going? World J Gastrointest Surg 2015; 7: 138–44.
    2. Young SJ. Irreversible electroporation and the pancreas: What we know and where we are going? World J Gastrointest Surg. 2015;7:138–44.
    1. 46. Scheffer HJ, Nielsen K, de Jong MC, van Tilborg AA, Vieveen JM, Bouwman AR, et al. Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy. J Vasc interv Radiol 2014; 25: 997–1011.
    2. Scheffer HJ, Nielsen K, de Jong MC, van Tilborg AA, Vieveen JM, Bouwman AR. et al. Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy. J Vasc interv Radiol. 2014;25:997–1011.
    1. 47. Trueba-Arguinarena FJ, de Prado-Otero DS, Poves-Alvarez R. Pancreatic adenocarcinoma treated with irreversible electroporation Case Report: first experience and outcome. Medicine (Baltimore) 2015; 94: e946.
    2. Trueba-Arguinarena FJ, de Prado-Otero DS, Poves-Alvarez R. Pancreatic adenocarcinoma treated with irreversible electroporation Case Report: first experience and outcome. Medicine (Baltimore) 2015;94:e946.
    1. 48. Gall TM, Thompson Z, Dinneen EP, Sodergren M, Pai M, Frampton AE, et al. Surgical techniques for improving outcomes in pancreatic ductal adenocarcinoma. Expert Rew Gastroenter Hepatol 2014; 8: 241–6.
    2. Gall TM, Thompson Z, Dinneen EP, Sodergren M, Pai M, Frampton AE. et al. Surgical techniques for improving outcomes in pancreatic ductal adenocarcinoma. Expert Rew Gastroenter Hepatol. 2014;8:241–6.
    1. 49. Weiss MJ, Wolfgang CL. Irreversible electroporation: a novel pancreatic cancer therapy. Curr Probl Cancer 2013; 37: 262–5.
    2. Weiss MJ, Wolfgang CL. Irreversible electroporation: a novel pancreatic cancer therapy. Curr Probl Cancer. 2013;37:262–5.
    1. 50. Martin RG, II, McFarland K, Ellis S, Velanovich V. Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival. Ann Surg Oncol 2013; 20: 443–9.
    2. Martin RG II, McFarland K, Ellis S, Velanovich V. Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival. Ann Surg Oncol. 2013;20:443–9.
    1. 51. Long G, Bakos G, Shires PK, Gritter L, Crissman JW, Harris JL, et al. Histological and finite element analysis of cell death due to irreversible electroporation. Technol Cancer Res Treat 2014; 13: 561–9.
    2. Long G, Bakos G, Shires PK, Gritter L, Crissman JW, Harris JL. et al. Histological and finite element analysis of cell death due to irreversible electroporation. Technol Cancer Res Treat. 2014;13:561–9.
    1. 52. Ball C, Thomson KR, Kavnoudias H. Irreversible electroporation: a new challenge in “out of operating theater” anesthesia. Anesth Analg 2010; 110: 1305–9.
    2. Ball C, Thomson KR, Kavnoudias H. Irreversible electroporation: a new challenge in “out of operating theater” anesthesia. Anesth Analg. 2010;110:1305–9.
    1. 53. Mali B, Gorjup V, Edhemovic I, Brecelj E, Cemazar M, Sersa G, et al. Electrochemotherapy of colorectal liver metastases - an observational study of its effects on the electrocardiogram. Biomed Eng Online 2015; 14(Suppl 3): S5.
    2. Mali B, Gorjup V, Edhemovic I, Brecelj E, Cemazar M, Sersa G. et al. Electrochemotherapy of colorectal liver metastases - an observational study of its effects on the electrocardiogram. Biomed Eng Online. 2015;14(Suppl 3):S5.
    1. 54. Bagla S, Papadouris D. Percutaneous irreversible electroporation of surgically unresectable pancreatic cancer: a case report. Journal of vascular and interventional radiology: J Vasc Interv Radiol 2012; 23: 142–5.
    2. Bagla S, Papadouris D. Percutaneous irreversible electroporation of surgically unresectable pancreatic cancer: a case report. Journal of vascular and interventional radiology: J Vasc Interv Radiol. 2012;23:142–5.
    1. 55. Mansson C, Bergenfeldt M, Brahmstaedt R, Karlson BM, Nygren P, Nilsson A. Safety and preliminary efficacy of ultrasound-guided percutaneous irreversible electroporation for treatment of localized pancreatic cancer. Anticancer Res 2014; 34: 289–93.
    2. Mansson C, Bergenfeldt M, Brahmstaedt R, Karlson BM, Nygren P, Nilsson A. Safety and preliminary efficacy of ultrasound-guided percutaneous irreversible electroporation for treatment of localized pancreatic cancer. Anticancer Res. 2014;34:289–93.
    1. 56. Paiella S, Butturini G, Frigerio I, Salvia R, Armatura G, Bacchion M, et al. Safety and feasibility of irreversible electroporation (IRE) in patients with locally advanced pancreatic cancer: results of a prospective study. Digest Surg 2015; 32: 90–7.
    2. Paiella S, Butturini G, Frigerio I, Salvia R, Armatura G, Bacchion M. et al. Safety and feasibility of irreversible electroporation (IRE) in patients with locally advanced pancreatic cancer: results of a prospective study. Digest Surg. 2015;32:90–7.
    1. 57. Martin RC, McFarland K, Ellis S, Velanovich V. Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival. Ann Surg Oncol 2013; 20(Suppl 3): S443-9.
    2. Martin RC, McFarland K, Ellis S, Velanovich V. Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival. Ann Surg Oncol. 2013;20(Suppl 3):S443–9.
    1. 58. Martin RC, Philips P, Ellis S, Hayes D, Bagla S. Irreversible electroporation of unresectable soft tissue tumors with vascular invasion: effective palliation. BMC Cancer 2014; 14: 540.
    2. Martin RC, Philips P, Ellis S, Hayes D, Bagla S. Irreversible electroporation of unresectable soft tissue tumors with vascular invasion: effective palliation. BMC Cancer. 2014;14:540.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren